CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary
hypertension (PH) do not fit well into the current classification system and treatments for
pulmonary hypertension. This study aims to better understand patients with ILD-PH and
scleroderma and to determine if treatment with Macitentan is beneficial.